Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs Pralatrexate (Primary) ; Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 17 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to lack of funding.
- 31 Aug 2018 Biomarkers information updated
- 07 Mar 2018 Planned initiation date changed from 1 Jan 2018 to 1 Sep 2018.